Enoumena Therapeutics Names Linda Lu Wittenberg Chief Medical Officer
MONTREAL, October 14, 2026 — Enoumena Therapeutics Inc. today announced that Linda Lu Wittenberg has been named Chief Medical Officer. Linda has worked closely with founder Peter Melnyk as Enoumena developed its medical strategy and prepared for the Canadian commercialization of SIBBORAN® (landiolol).
“Linda and I have worked closely to build a medical strategy grounded in the evidence and the realities of Canadian care,” said Peter Melnyk, PhD, President and CEO of Enoumena Therapeutics. “Linda brings extensive medical affairs experience, sound judgment and the ability to constructively challenge our thinking. Our work together has made Enoumena’s plans stronger, and I’m delighted she is taking on this role.”
As Chief Medical Officer, Linda will lead Enoumena’s medical strategy and medical affairs, ensuring that clinical insights inform the company’s priorities and guide its scientific exchange with Canadian healthcare professionals.
“Bringing a medicine to Canada also means helping healthcare teams understand where it fits and how to use it appropriately,” said Linda Lu Wittenberg, Chief Medical Officer of Enoumena Therapeutics. “I want Enoumena to stay close to the people delivering care and make their clinical questions a priority, beginning with SIBBORAN® and carrying that commitment across our portfolio.”
Linda brings 30 years of experience in healthcare and the pharmaceutical industry. After beginning her career in nuclear medicine, she spent more than 22 years at Sanofi, progressing from clinical research through medical science liaison and medical digital management to medical advisor roles. She also leads LuWitt Consulting, where she advises on medical strategy and clinical research and mentors medical affairs and healthcare professionals. Her experience spans cardiovascular medicine, diabetes, oncology and other therapeutic areas.
The appointment follows Enoumena’s October 8, 2026 announcement of an exclusive agreement with AOP Health to commercialize SIBBORAN® in Canada.
About Enoumena Therapeutics Inc.
Enoumena Therapeutics Inc. is a Canadian specialty pharmaceutical company that partners with Canadian and international pharmaceutical and biotechnology companies to commercialize innovative medicines in Canada. Enoumena brings together Canadian market access, medical affairs and commercialization expertise with a focused operating model for specialty and hospital-based products. For more information, visit enoumenatx.com.
Media Contact
Enoumena Therapeutics Inc.
← All news